Henry Schein, Inc. (HSIC) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
HSIC price how computed
Forward Fair Value verdict
Fairly valuedHSIC is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $84.01
- Sector
- Healthcare
- 12-month range
- $62.32–$90.86
- Market cap
- $9.36B
- From 52-week high
- -7.5%
- Shares outstanding
- 111M
- Rank in Healthcare by discount to fair value
- #47 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Henry Schein, Inc. is a distributor of health care products and services to dental, medical, animal health, and specialty practices. The company operates globally, serving customers in North America, Europe, the Middle East, Africa, and the Asia Pacific region.
HSIC currently ranks #47 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $9.36B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $13.6B
- Net margin
- 3.0%
- EPS (TTM)
- $5.31
- Gross margin
- 31.8%
- Debt / equity
- 1.21
- Revenue growth (3-yr avg)
- 3.1%
- Shares outstanding
- 111M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 56 · neutral
- 50-day average
- $87.38
- 200-day average
- $80.67
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.1%)
2026-03 ▲ beat (+8.2%)
2025-12 ▲ beat (+3.1%)
2025-09 ▲ beat (+7.8%)
2025-06 ▼ miss (-7.6%)
2025-03 ▲ beat (+3.6%)
2024-12 ▼ miss (-1.6%)
2024-09 ▲ beat (+4.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 7 hold · 1 sell (16 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $96.9
- Target vs last price
- +15.3%
What our data shows for HSIC
- Our model validated 17 trailing price-to-earnings windows for HSIC, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $62.32–$90.86.
- The 14-day relative strength index sits at a neutral 56.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for HSIC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent HSIC news
TickrTrends' derived news-sentiment signal for HSIC is currently leaning positive, computed from recent coverage.
- Henry Schein (HSIC) Expands Revolving Credit Facility to $1.25 Billion and Extends Maturity to 2031 (gurufocus.com, 2026-09-22)
TickrTrends take: Henry Schein's expansion of its revolving credit facility to 1 billion dollars with an extension to 2031 provides the company with increased financial flexibility and reduced near-term refinancing risk in the healthcare distribution sector. Given TickrTrends' assessment that HSIC is fairly valued, investors should monitor how the company deploys this enhanced liquidity capacity, as strategic investments or acquisitions funded through the facility could materially affect future profitability and cash flow relative to current valuation levels. The extended maturity timeline also removes a potential refinancing event that could have created balance sheet pressure during the period through 2031. - Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher (NASDAQ:HSIC) (seekingalpha.com, 2026-09-19)
TickrTrends take: Henry Schein operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. The recent price movement noted in this article suggests the market is responding positively to the company's performance, though investors should monitor whether the stock's gains bring valuation metrics beyond fair value levels. For valuation-conscious investors, tracking fundamental metrics like earnings growth and cash flow generation relative to the current price will be important to determine if the recent move has shifted the company's valuation profile. - Henry Schein: Growth Is Improving, But The Valuation Stays Cheap (NASDAQ:HSIC) (seekingalpha.com, 2026-09-16)
TickrTrends take: Henry Schein operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. The headline indicates that the company's growth trajectory is strengthening, which could influence how the market perceives its valuation multiples going forward. Investors focused on valuation metrics should monitor whether improving growth translates into multiple expansion or whether the stock maintains its current pricing posture relative to sector peers.
What people are saying
Follow the HSIC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — HSIC traded in a mixed trend this week after the previous week's uptrend, according to TickrTrends' 50/200-day trend state indicator. The stock's sector discount rank improved to number 65 from number 70, indicating it trades at a smaller discount relative to other Healthcare sector stocks. At current levels, HSIC is assessed as fairly valued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is HSIC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), HSIC is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is HSIC's TickrTrends verdict?
HSIC's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does HSIC compare to other Healthcare stocks?
HSIC ranks #47 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is HSIC overbought or oversold?
HSIC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does HSIC report earnings next?
HSIC's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does HSIC usually beat earnings estimates?
Over its last 8 reported quarters HSIC beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about HSIC?
Of 16 analysts covering HSIC, 8 rate it a buy, 7 a hold and 1 a sell - buy-leaning, with a consensus price target of $96.9 (+15.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
HSIC vs ENSG · HSIC vs EXEL · HSIC vs HCSG · HSIC vs INVA · HSIC vs IQV